|
1
|
Pabla N and Dong Z: Cisplatin
nephrotoxicity: Mechanisms and renoprotective strategies. Kidney
Int. 73:994–1007. 2008.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Perazella MA and Moeckel GW:
Nephrotoxicity from chemotherapeutic agents: Clinical
manifestations, pathobiology and prevention/therapy. Semin Nephrol.
30:570–581. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Didier Portilla, A Mazin Safar and Melissa
L Shannon: Cisplatin nephrotoxicity. Post TW, ed. UpToDate.
Waltham, MA: UptoDate Inc. https://www.uptodate.com/contents/cisplatin-nephrotoxicity.
Accessed February 26, 2019.
|
|
4
|
Dobyan DC, Levi J, Jacobs C, Kosek J and
Weiner MW: Mechanism of cis-platinum nephrotoxicity: II.
Morphologic observations. J Pharmacol Exp Ther. 213:551–556.
1980.PubMed/NCBI
|
|
5
|
Sobrero A, Guglielmi A, Aschele C and
Rosso R: Current strategies to reduce cisplatin toxicity. J
Chemother. 2:3–7. 1990.PubMed/NCBI View Article : Google Scholar
|
|
6
|
de Jongh FE, van Veen RN, Veltman SJ, de
Wit R, van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ,
Stoter G and Verweij J: Weekly high-dose cisplatin is a feasible
treatment option: Analysis on prognostic factors for toxicity in
400 patients. Br J Cancer. 88:1199–1206. 2003.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hinai Y, Motoyama S, Niioka T and Miura M:
Absence of effect of SLC22A2 genotype on cisplatin-induced
nephrotoxicity in oesophageal cancer patients receiving cisplatin
and 5-fluorouracil: Report of results discordant with those of
earlier studies. J Clin Pharm Ther. 38:498–503. 2013.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Zhang J and Zhou W: Ameliorative effects
of SLC22A2 gene polymorphism 808 G/T and cimetidine on
cisplatin-induced nephrotoxicity in Chinese cancer patients. Food
Chem Toxicol. 50:2289–2293. 2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Iwata K, Aizawa K, Kamitsu S, Jingami S,
Fukunaga E, Yoshida M, Yoshimura M, Hamada A and Saito H: Effects
of genetic variants in SLC22A2 organic cation transporter 2 and
SLC47A1 multidrug and toxin extrusion 1 transporter on
cisplatin-induced adverse events. Clin Exp Nephrol. 16:843–851.
2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Filipski KK, Mathijssen RH, Mikkelsen TS,
Schinkel AH and Sparreboom A: Contribution of organic cation
transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin
Pharmacol Ther. 86:396–402. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Tzvetkov MV, Behrens G, O'Brien VP,
Hohloch K, Brockmöller J and Benöhr P: Pharmacogenetic analyses of
cisplatin-induced nephrotoxicity indicate a renoprotective effect
of ERCC1 polymorphisms. Pharmacogenomics. 12:1417–1427.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Windsor RE, Strauss SJ, Kallis C, Wood NE
and Whelan JS: Germline genetic polymorphisms may influence
chemotherapy response and disease outcome in osteosarcoma: A pilot
study. Cancer. 118:1856–1867. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Chang C, Hu Y, Hogan SL, Mercke N, Gomez
M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM and Joy MS:
Pharmacogenomic variants may influence the urinary excretion of
novel kidney injury biomarkers in patients receiving cisplatin. Int
J Mol Sci. 18(1333)2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zazuli Z, Vijverberg S, Slob E, Liu G,
Carleton B, Veltman J, Baas P, Masereeuw R and Maitland-van der Zee
AH: Genetic variations and cisplatin nephrotoxicity: A systematic
review. Front Pharmacol. 9(1111)2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pavlidis P and Nobel WS: Analysis of
strain and regional variation in gene expression in mouse brain.
Genome Biol. 2(Research0042)2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Howe EA, Sinha R, Schlauch D and
Quackenbush J: RNA-Seq analysis in MeV. Bioinformatics.
27:3209–3210. 2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hesketh PJ, Kris MG, Basch E, Bohlke K,
Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina
SB, et al: Antiemetics: American society of clinical oncology
clinical practice guideline update. J Clin Oncol. 35:3240–3261.
2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Dilruba S and Kalayda GV: Platinum-based
drugs: Past, present and future. Cancer Chemother Pharmacol.
77:1103–1124. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Innocenti F, Schilsky RL, Ramírez J,
Janisch L, Undevia S, House LK, Das S, Wu K, Turcich M, Marsh R, et
al: Dose-finding and pharmacokinetic study to optimize the dosing
of irinotecan according to the UGT1A1 genotype of patients with
cancer. J Clin Oncol. 32:2328–2334. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Henricks LM, Opdam FL, Beijnen JH, Cats A
and Schellens JHM: DPYD genotype-guided dose individualization to
improve patient safety of fluoropyrimidine therapy: Call for a drug
label update. Ann Oncol. 28:2915–2922. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Relling MV, Gardner EE, Sandborn WJ,
Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE and
Klein TE: Clinical Pharmacogenetics Implementation Consortium.
Clinical pharmacogenetics implementation consortium guidelines for
thiopurine methyltransferase genotype and thiopurine dosing. Clin
Pharmacol Ther. 89:387–391. 2011.PubMed/NCBI View Article : Google Scholar
|
